Robert H. Mach, Britton Chance Professor of Radiology, University of Pennsylvania will be presenting a talk as part of the PET-RTRC Seminar
PARP inhibitors (PARPi) have proven to be an important class of compounds for treating cancer patients having BRCA1/2 mutations or other deficiencies in homologous recombination repair. Unfortunately, ~50% of patients having BRCA1/2 mutations do not respond to PARPi, indicating that better biomarkers are needed to identify which patients are likely to benefit from this type of treatment.
If you are a member of the WashU community, login with your WUSTL Key to interact with events, personalize your calendar, and get recommendations.Login with WUSTL Key
If you are not a member of the WashU community, please login via one of the options below to interact with our calendar.